

## UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS

Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR		ATTORNEY DOCKET NO.
09/396,52	3 09/15/	99 VERMEULIN	N	275102221021
- Kate u mu	KATE H MURASHIGE HM12/			EXAMINER
MORRISON	LIP	0 SI	ULLIVAN, P	
2000 PENNSYLVANIA AVENUE		/ENUE NW	ART UNIT	PAPER NUMBER
SUITE 550 WASHINGTO	0 N DC 2000 <del>6</del> -	-1888	162	arphi
•			DATE MAILED	: N3/29/01

Please find below and/or attached an Office communication concerning this application or proceeding.

**Commissioner of Patents and Trademarks** 

## Application No. 09/396,523

Applicant(s)

Vermeulin et al.

## Office Action Summary

Examiner

Peter O'Sullivan

Group Art Unit 1621



Responsive to communication(s) filed on	
☐ This action is <b>FINAL</b> .	
Since this application is in condition for allowance in accordance with the practice under Ex parte Q	e except for formal matters, prosecution as to the merits is closed luayle, 1935 C.D. 11; 453 O.G. 213.
is longer, from the mailing date of this communication	tion is set to expire month(s), or thirty days, whichever on. Failure to respond within the period for response will cause the 3). Extensions of time may be obtained under the provisions of
Disposition of Clalms	
	is/are pending in the application.
Of the above, claim(s)	is/are withdrawn from consideration.
☐ Claim(s)	is/are allowed.
·	is/are rejected.
	is/are objected to.
	are subject to restriction or election requirement.
☐ received	is/are objected to by the Examiner.  is _approved _disapproved.  ier.  Examiner.  sign priority under 35 U.S.C. § 119(a)-(d).  ED copies of the priority documents have been  e/Serial Number)  on from the International Bureau (PCT Rule 17.2(a)).
Attachment(s)  Notice of References Cited, PTO-892 Information Disclosure Statement(s), PTO-144 Interview Summary, PTO-413 Notice of Draftsperson's Patent Drawing Revie	ew, PTO-948
SEE OFFICE A	ACTION ON THE FOLLOWING PAGES

Page 2

Application/Control Number: 09/396,523

Art Unit: 1621

1. Claims 1-29 are generic to a plurality of disclosed patentably distinct species comprising,

for example, sulfonamides or carboxamides. Applicant is required under 35 U.S.C. 121 to elect a

single disclosed species, even though this requirement is traversed.

Should applicant traverse on the ground that the species are not patentably distinct,

applicant should submit evidence or identify such evidence now of record showing the species to

be obvious variants or clearly admit on the record that this is the case. In either instance, if the

examiner finds one of the inventions unpatentable over the prior art, the evidence or admission

may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

2. Again, applicants are requested to elect a single disclosed species, i.e. a single

compound.

Applicant is advised that the reply to this requirement to be complete must include an

election of the invention to be examined even though the requirement be traversed (37

CFR 1.143).

3. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the

inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently

named inventors is no longer an inventor of at least one claim remaining in the application. Any

amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the

fee required under 37 CFR 1.17(i).

4. Any inquiry concerning this communication or earlier communications from the examiner

should be directed to Peter O'Sullivan whose telephone number is (703) 308-4526.

PETER O'SULLIVAN PRIMARY EXAMINER